The pathogenesis of central serous chorioretinopathy (CSC) is still not fully understood. The involvement of corticosteroids is undisputed, although their exact role has not been clarified; other parts of the underlying mechanism of CSC have been mainly elucidated by imaging techniques such as fluorescein and indocyanine green angiography. Even though most cases of CSC are self-limiting, severe as well as recurrent courses exist, and for these patients only a limited number of treatment options are available: laser photocoagulation, with a risk of scotoma and choroidal neovascularization, and photodynamic therapy. In this review article, we give an overview of its epidemiology, the current understanding of its pathogenesis as well as systemic and ocular risk factors. We illuminate modern diagnostic tools as well as current treatment options in the context of CSC, particularly in the light of a better understanding of corticosteroids and their receptors involved in its pathogenesis.

Keywords:
Central serous chorioretinopathy, Pathogenesis, Epidemiology, Risk factors
1.
von Graefe A: Über zentrale rezidivierende Retinitis. Graefes Arch Clin Exp Ophthalmol 1866;12:211-215.
2.
Horniker E: Über eine Form von zentraler Retinitis auf angioneurotischer Grundlage (Retinitis centralis angioneurotica). Graefes Arch Clin Exp Ophthalmol 1929;123:286-360.
3.
Horniker E: Su di una forma retinite centrale di origine vasoneurotica (retinite central capillaro spastica). Ann Ottal 1927;55:578-600.
4.
Gifford SR, Marquardt G: Central angiospastic retinopathy. Arch Ophthalmol 1939;21:211-228.
5.
Maumenee AE: Macular diseases: clinical manifestations. Trans Am Acad Ophthalmol Otolaryngol 1965;69:605-613.
6.
Gass JD: Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63(suppl):1-139.
7.
Meyerle CB, Spaide RF: Central serous chorioretinopathy; in Albert DM, Miller JW, Azar DT, Blodi BA (eds): Albert and Jakobiec's Principles and Practice of Ophthalmology. Philadelphia, Saunders, 2008, vol 3, pp 1871-1880.
8.
Wang M, Munch IC, Hasler PW, Prünte C, Larsen M: Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-145.
9.
Spitznas M, Huke J: Number, shape, and topography of leakage points in acute type I central serous retinopathy. Graefes Arch Clin Exp Ophthalmol 1987;225:437-440.
10.
Castro-Correia J, Coutinho MF, Rosas V, Maia J: Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992;81:379-386.
11.
Wang M, Sander B, la Cour M, Larsen M: Clinical characteristics of subretinal deposits in central serous chorioretinopathy. Acta Ophthalmol Scand 2005;83:691-696.
12.
Tittl MK, Spaide RF, Wong D, Pilotto E, Yannuzzi LA, Fisher YL, Freund B, Guyer DR, Slakter JS, Sorenson JA: Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 1999;128:63-68.
13.
Gilbert CM, Owens SL, Smith PD, Fine SL: Long-term follow-up of central serous chorioretinopathy. Br J Ophthalmol 1984;68:815-820.
14.
Jamil AZ, Mirza KA, Qazi ZU, Iqbal W, Khaliq J, Fawad-ur R, Ahmed A: Features of central serous chorioretinopathy presenting at a tertiary care hospital in Lahore. J Pak Med Assoc 2013;63:478-482.
15.
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP: The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002. Ophthalmology 2008;115:169-173.
16.
Spaide RF: Central serous chorioretinopathy; in Krieglstein GK, Weinreb RN (eds): Medical Retina. Heidelberg, Springer, 2005, pp 77-95.
17.
Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996;103:2070-2079, discussion 2079-2080.
18.
Tsai DC, Chen SJ, Huang CC, Chou P, Chung CM, Huang PH, Lin SJ, Chen JW, Chen TJ, Leu HB, Chan WL: Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study. PLoS One 2013;8:e66858.
19.
Gäckle HC, Lang GE, Freissler KA, Lang GK: Central serous chorioretinopathy: clinical, fluorescein angiography and demographic aspects (in German). Ophthalmologe 1998;95:529-533.
20.
Kim YC, Kim SD, Kim KS: A case of idiopathic central serous chorioretinopathy in a 12-year-old male treated with bevacizumab. Korean J Ophthalmol 2012;26:391-393.
21.
Alwassia AA, Adhi M, Duker JS: Bilateral simultaneous central serous chorioretinopathy in a teenage girl with systemic arterial hypertension. Int Ophthalmol 2013;33:79-82.
22.
Chan WM, Lai TY, Tano Y, Liu DT, Li KK, Lam DS: Photodynamic therapy in macular diseases of Asian populations: when East meets West. Jpn J Ophthalmol 2006;50:161-169.
23.
Yannuzzi LA: Type-A behavior and central serous chorioretinopathy. Retina 1987;7:111-131.
24.
Balo KP, Mihluedo H: Idiopathic central serous chorioretinopathy: two case reports observed in Togo (in French). Med Trop (Mars) 1996;56:381-383.
25.
Katsimpris JM, Pournaras CJ, Sehgelmeble CW, Petropoulos IK: Severe bilateral central serous chorioretinopathy in a black patient: 16 years follow-up. Graefes Arch Clin Exp Ophthalmol 2007;245:460-463.
26.
Desai UR, Alhalel AA, Campen TJ, Schiffman RM, Edwards PA, Jacobsen GR: Central serous chorioretinopathy in African Americans. J Natl Med Assoc 2003;95:553-559.
27.
Nicholson B, Noble J, Forooghian F, Meyerle C: Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013;58:103-126.
28.
Uyama M, Matsunaga H, Matsubara T, Fukushima I, Takahashi K, Nishimura T: Indocyanine green angiography and pathophysiology of multifocal posterior pigment epitheliopathy. Retina 1999;19:12-21.
29.
Yannuzzi LA: Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010;149:361-363.
30.
Okushiba U, Takeda M: Study of choroidal vascular lesions in central serous chorioretinopathy using indocyanine green angiography (in Japanese). Nihon Ganka Gakkai Zasshi 1997;101:74-82.
31.
Prünte C, Flammer J: Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26-34.
32.
Spaide RF, Hall L, Haas A, Campeas L, Yannuzzi LA, Fisher YL, Guyer DR, Slakter JS, Sorenson JA, Orlock DA: Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-213.
33.
Guyer DR, Yannuzzi LA, Slakter JS, Sorenson JA, Ho A, Orlock D: Digital indocyanine green videoangiography of central serous chorioretinopathy. Arch Ophthalmol 1994;112:1057-1062.
34.
Hayashi K, Hasegawa Y, Tokoro T: Indocyanine green angiography of central serous chorioretinopathy. Int Ophthalmol 1986;9:37-41.
35.
Scheider A, Nasemann JE, Lund OE: Fluorescein and indocyanine green angiographies of central serous choroidopathy by scanning laser ophthalmoscopy. Am J Ophthalmol 1993;115:50-56.
36.
Hussain D, Gass JD: Idiopathic central serous chorioretinopathy. Ind J Ophthalmol 1998;46:131-137.
37.
Slakter JS, Yannuzzi LA, Guyer DR, Sorenson JA, Orlock DA: Indocyanine-green angiography. Curr Opin Ophthalmol 1995;6:25-32.
38.
Gupta V, Gupta P, Dogra MR, Gupta A: Spontaneous closure of retinal pigment epithelium microrip in the natural course of central serous chorioretinopathy. Eye (Lond) 2010;24:595-599.
39.
Goldstein BG, Pavan PR: ‘Blow-outs' in the retinal pigment epithelium. Br J Ophthalmol 1987;71:676-681.
40.
Piccolino FC, Borgia L: Central serous chorioretinopathy and indocyanine green angiography. Retina 1994;14:231-242.
41.
Piccolino FC, Borgia L, Zinicola E, Zingirian M: Indocyanine green angiographic findings in central serous chorioretinopathy. Eye (Lond) 1995;9:324-332.
42.
Spitznas M: Pathogenesis of central serous retinopathy: a new working hypothesis. Graefes Arch Clin Exp Ophthalmol 1986;224:321-324.
43.
Bouzas EA, Karadimas P, Pournaras CJ: Central serous chorioretinopathy and glucocorticoids. Surv Ophthalmol 2002;47:431-448.
44.
Haimovici R, Koh S, Gagnon DR, Lehrfeld T, Wellik S: Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-249.
45.
Sun J, Tan J, Wang Z, Yang H, Zhu X, Li L: Effect of catecholamine on central serous chorioretinopathy. J Huazhong Univ Sci Technolog Med Sci 2003;23:313-316.
46.
Thoelen AM, Bernasconi PP, Schmid C, Messmer EP: Central serous chorioretinopathy associated with a carcinoma of the adrenal cortex. Retina 2000;20:98-99.
47.
Loo JL, Lee SY, Ang CL: Can long-term corticosteroids lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids. Ann Acad Med Singapore 2006;35:496-499.
48.
Polak BC, Baarsma GS, Snyers B: Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment. Br J Ophthalmol 1995;79:922-925.
49.
Browning DJ: Nadolol in the treatment of central serous retinopathy. Am J Ophthalmol 1993;116:770-771.
50.
Bouzas EA, Scott MH, Mastorakos G, Chrousos GP, Kaiser-Kupfer MI: Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993;111:1229-1233.
51.
Garg SP, Dada T, Talwar D, Biswas NR: Endogenous cortisol profile in patients with central serous chorioretinopathy. Br J Ophthalmol 1997;81:962-964.
52.
Barnes PJ: Corticosteroid effects on cell signalling. Eur Respir J 2006;27:413-426.
53.
Sakaue M, Hoffman BB: Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. J Clin Invest 1991;88:385-389.
54.
Oikarinen AI, Uitto J, Oikarinen J: Glucocorticoid action on connective tissue: from molecular mechanisms to clinical practice. Med Biol 1986;64:221-230.
55.
Imasawa M, Ohshiro T, Gotoh T, Imai M, Iijima H: Central serous chorioretinopathy following vitrectomy with intravitreal triamcinolone acetonide for diabetic macular oedema. Acta Ophthalmol Scand 2005;83:132-133.
56.
Baumal CR, Martidis A, Truong SN: Central serous chorioretinopathy associated with periocular corticosteroid injection treatment for HLA-B27-associated iritis. Arch Ophthalmol 2004;122:926-928.
57.
Friedman M, Thoresen CE, Gill JJ, Ulmer D, Powell LH, Price VA, Brown B, Thompson L, Rabin DD, Breall WS, et al: Alteration of type A behavior and its effect on cardiac recurrences in post myocardial infarction patients: summary results of the recurrent coronary prevention project. Am Heart J 1986;112:653-665.
58.
Errera MH, Kohly RP, da Cruz L: Pregnancy-associated retinal diseases and their management. Surv Ophthalmol 2013;58:127-142.
59.
Casella AM, Berbel RF, Bressanim GL, Malaguido MR, Cardillo JA: Helicobacter pylori as a potential target for the treatment of central serous chorioretinopathy. Clinics (Sao Paulo) 2012;67:1047-1052.
60.
Eom Y, Oh J, Kim SW, Huh K: Systemic factors associated with central serous chorioretinopathy in Koreans. Korean J Ophthalmol 2012;26:260-264.
61.
Weenink AC, Borsje RA, Oosterhuis JA: Familial chronic central serous chorioretinopathy. Ophthalmologica 2001;215:183-187.
62.
Spahn C, Wiek J, Burger T, Hansen L: Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003;87:704-708.
63.
Fawzi AA, Holland GN, Kreiger AE, Heckenlively JR, Arroyo JG, Cunningham ET Jr: Central serous chorioretinopathy after solid organ transplantation. Ophthalmology 2006;113:805-813e5.
64.
Kanski J, Bowling B: Clinical Ophthalmology: A Systemic Approach. London, Elsevier, 2011.
65.
Karakus SH, Basarir B, Pinarci EY, Kirandi EU, Demirok A: Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes. Eye (Lond) 2013;27:612-620.
66.
Lim SH, Chang W, Sagong M: Efficacy of half-fluence photodynamic therapy depending on the degree of choroidal hyperpermeability in chronic central serous chorioretinopathy. Eye (Lond) 2013;27:353-362.
67.
Chen SN, Hwang JF, Tseng LF, Lin CJ: Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage. Ophthalmology 2008;115:2229-2234.
68.
Ficker L, Vafidis G, While A, Leaver P: Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1988;72:829-834.
69.
Fok AC, Chan PP, Lam DS, Lai TY: Risk factors for recurrence of serous macular detachment in untreated patients with central serous chorioretinopathy. Ophthalmic Res 2011;46:160-163.
70.
Gueudry J, Genevois O, Adam PA, Muraine M, Brasseur G: Retinal pigment epithelium tear following central serous chorioretinopathy. Acta Ophthalmol 2009;87:691-693.
71.
Ishida Y, Kato T, Minamoto A, Yokoyama T, Jian K, Mishima HK: Retinal pigment epithelial tear in a patient with central serous chorioretinopathy treated with corticosteroids. Retina 2004;24:633-636.
72.
Akiyama K, Kawamura M, Ogata T, Tanaka E: Retinal vascular loss in idiopathic central serous chorioretinopathy with bullous retinal detachment. Ophthalmology 1987;94:1605-1609.
73.
Gass JD: Bullous retinal detachment: an unusual manifestation of idiopathic central serous choroidopathy. Am J Ophthalmol 1973;75:810-821.
74.
Friberg TR, Eller AW: Serous retinal detachment resembling central serous chorioretinopathy following organ transplantation. Graefes Arch Clin Exp Ophthalmol 1990;228:305-309.
75.
Shahin MM: Angiographic characteristics of central serous chorioretinopathy in an Egyptian population. Int J Ophthalmol 2013;6:342-345.
76.
Yanuzzi L: The Retinal Atlas. Philadelphia, Saunders, 2010.
77.
Kitaya N, Nagaoka T, Hikichi T, Sugawara R, Fukui K, Ishiko S, Yoshida A: Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003;87:709-712.
78.
Stanga PE, Lim JI, Hamilton P: Indocyanine green angiography in chorioretinal diseases: indications and interpretation - an evidence-based update. Ophthalmology 2003;110:15-21, quiz 22-23.
79.
Shiraki K, Moriwaki M, Matsumoto M, Yanagihara N, Yasunari T, Miki T: Long-term follow-up of severe central serous chorioretinopathy using indocyanine green angiography. Int Ophthalmol 1997;21:245-253.
80.
Smretschnig E, Ansari-Shahrezaei S, Hagen S, Glittenberg C, Krebs I, Binder S: Half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Retina 2013;33:316-323.
81.
Shin JY, Woo SJ, Yu HG, Park KH: Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina 2011;31:119-126.
82.
Hee MR, Puliafito CA, Wong C, Reichel E, Duker JS, Schuman JS, Swanson EA, Fujimoto JG: Optical coherence tomography of central serous chorioretinopathy. Am J Ophthalmol 1995;120:65-74.
83.
Yang L, Jonas JB, Wei W: Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 2013;91:e358-e362.
84.
Ahn SE, Oh J, Oh JH, Oh IK, Kim SW, Huh K: Three-dimensional configuration of subretinal fluid in central serous chorioretinopathy. Invest Ophthalmol Vis Sci 2013;54:5944-5952.
85.
Imamura Y, Fujiwara T, Margolis R, Spaide RF: Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009;29:1469-1473.
86.
Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T: Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011;31:1603-1608.
87.
Brandl C, Helbig H, Gamulescu MA: Choroidal thickness measurements during central serous chorioretinopathy treatment. Int Ophthalmol 2014;34:7-13.
88.
Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, Matsumoto A, Yoshimura N: Assessment of macular choroidal thickness by optical coherence tomography and angiographic changes in central serous chorioretinopathy. Ophthalmology 2012;119:1666-1678.
89.
Matsumoto H, Kishi S, Otani T, Sato T: Elongation of photoreceptor outer segment in central serous chorioretinopathy. Am J Ophthalmol 2008;145:162-168.
90.
Kim SW, Oh J, Huh K: Correlations among various functional and morphological tests in resolved central serous chorioretinopathy. Br J Ophthalmol 2012;96:350-355.
91.
Ojima Y, Hangai M, Sasahara M, Gotoh N, Inoue R, Yasuno Y, Makita S, Yatagai T, Tsujikawa A, Yoshimura N: Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography. Ophthalmology 2007;114:2197-2207.
92.
Almeida A, Kaliki S, Shields CL: Autofluorescence of intraocular tumours. Curr Opin Ophthalmol 2013;24:222-232.
93.
Hopkins J, Walsh A, Chakravarthy U: Fundus autofluorescence in age-related macular degeneration: an epiphenomenon? Invest Ophthalmol Vis Sci 2006;47:2269-2271.
94.
Göbel AP, Fleckenstein M, Schmitz-Valckenberg S, Brinkmann CK, Holz FG: Imaging geographic atrophy in age-related macular degeneration. Ophthalmologica 2011;226:182-190.
95.
Feeney L: Lipofuscin and melanin of human retinal pigment epithelium: fluorescence, enzyme cytochemical, and ultrastructural studies. Invest Ophthalmol Vis Sci 1978;17:583-600.
96.
Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995;36:718-729.
97.
Delori FC, Staurenghi G, Arend O, Dorey CK, Goger DG, Weiter JJ: In vivo measurement of lipofuscin in Stargardt's disease - fundus flavimaculatus. Invest Ophthalmol Vis Sci 1995;36:2327-2331.
98.
Wolf G: Lipofuscin, the age pigment. Nutr Rev 1993;51:205-206.
99.
Spaide RF, Klancnik JM Jr: Fundus autofluorescence and central serous chorioretinopathy. Ophthalmology 2005;112:825-833.
100.
von Ruckmann A, Fitzke FW, Fan J, Halfyard A, Bird AC: Abnormalities of fundus autofluorescence in central serous retinopathy. Am J Ophthalmol 2002;133:780-786.
101.
Eandi CM, Ober M, Iranmanesh R, Peiretti E, Yannuzzi LA: Acute central serous chorioretinopathy and fundus autofluorescence. Retina 2005;25:989-993.
102.
Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK: Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003;87:1453-1458.
103.
Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM: Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-763.
104.
Taban M, Boyer DS, Thomas EL, Taban M: Chronic central serous chorioretinopathy: photodynamic therapy. Am J Ophthalmol 2004;137:1073-1080.
105.
Ober MD, Yannuzzi LA, Do DV, Spaide RF, Bressler NM, Jampol LM, Angelilli A, Eandi CM, Lyon AT: Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088-2094.
106.
Koytak A, Erol K, Coskun E, Asik N, Öztürk H, Özertürk Y: Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. Retina 2010;30:1698-1703.
107.
Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS: Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006;90:869-874.
108.
Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS: Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008;28:85-93.
109.
Maruko I, Iida T, Sugano Y, Furuta M, Sekiryu T: One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011;31:1921-1927.
110.
Chan WM, Lai TY, Lai RY, Liu DT, Lam DS: Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008;115:1756-1765.
111.
Lim JW, Kang SW, Kim YT, Chung SE, Lee SW: Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy. Br J Ophthalmol 2011;95:514-517.
112.
Uetani R, Ito Y, Oiwa K, Ishikawa K, Terasaki H: Half-dose vs one-third-dose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond) 2012;26:640-649.
113.
Brinkmann R, Roider J, Birngruber R: Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol 2006;302:51-69.
114.
Roider J, Michaud NA, Flotte TJ, Birngruber R: Response of the retinal pigment epithelium to selective photocoagulation. Arch Ophthalmol 1992;110:1786-1792.
115.
Klatt C, Saeger M, Oppermann T, Pörksen E, Treumer F, Hillenkamp J, Fritzer E, Brinkmann R, Birngruber R, Roider J: Selective retina therapy for acute central serous chorioretinopathy. Br J Ophthalmol 2011;95:83-88.
116.
Brinkmann R, Schüle G, Neumann J, Framme C, Pörksen E, Elsner H, Theisen-Kunde D, Roider J, Birngruber R: Selective retina therapy: methods, technique, and online dosimetry (in German). Ophthalmologe 2006;103:839-849.
117.
Elsner H, Pörksen E, Klatt C, Bunse A, Theisen-Kunde D, Brinkmann R, Birngruber R, Laqua H, Roider J: Selective retina therapy in patients with central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2006;244:1638-1645.
118.
Klatt C, Elsner H, Pörksen E, Brinkmann R, Bunse A, Birngruber R, Roider J: Selective retina therapy in central serous chorioretinopathy with detachment of the pigmentary epithelium (in German). Ophthalmologe 2006;103:850-855.
119.
Leaver P, Williams C: Argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol 1979;63:674-677.
120.
Robertson DM, Ilstrup D: Direct, indirect, and sham laser photocoagulation in the management of central serous chorioretinopathy. Am J Ophthalmol 1983;95:457-466.
121.
Yap EY, Robertson DM: The long-term outcome of central serous chorioretinopathy. Arch Ophthalmol 1996;114:689-692.
122.
Yannuzzi LA, Slakter JS, Kaufman SR, Gupta K: Laser treatment of diffuse retinal pigment epitheliopathy. Eur J Ophthalmol 1992;2:103-114.
123.
Gonzalez C: Serous retinal detachment: value of acetazolamide (in French). J Fr Ophtalmol 1992;15:529-536.
124.
Pikkel J, Beiran I, Ophir A, Miller B: Acetazolamide for central serous retinopathy. Ophthalmology 2002;109:1723-1725.
125.
Zhao M, Valamanesh F, Celerier I, Savoldelli M, Jonet L, Jeanny JC, Jaisser F, Farman N, Behar-Cohen F: The neuroretina is a novel mineralocorticoid target: aldosterone up-regulates ion and water channels in Müller glial cells. FASEB J 2010;24:3405-3415.
126.
Zhao M, Celerier I, Bousquet E, Jeanny JC, Jonet L, Savoldelli M, Offret O, Curan A, Farman N, Jaisser F, Behar-Cohen F: Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest 2012;122:2672-2679.
127.
Bousquet E, Beydoun T, Zhao M, Hassan L, Offret O, Behar-Cohen F: Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2013;33:2096-2102.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.